Patient P-02281
Therapy response
Favorable
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Stable
Discontinuation risk
31%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S11
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability+7
- Toxicity-4
- Inflammatory activity+2
- Treatment adherence-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable45 min
worsening · -6.3 vs previous 14 d
Sleep duration
Wearable5.8 h
stable · -0.2 vs previous 14 d
Energy level
Daily log5.5/10
worsening · -0.5 vs previous 14 d
Steps
Wearable5,444
worsening · -732 vs previous 14 d
GI burden
Companion35.9/100
worsening · +14.3 vs previous 14 d
Adherence
Companion89.6 %
stable · +3.3 vs previous 14 d
Sleep quality
Wearable43.5/100
worsening · -3.1 vs previous 14 d
Glucose, CGM daily mean
CGM135 mg/dL
worsening · +10.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 60 from the failing basin, 28 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -7 next day on high-intake days · n 20
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-7supporter · 95%
- Ultra-processed food-2.3no signal · 39%
- Caffeine-1no signal · 15%
- Dietary fat load-0.9no signal · 16%
- Simple carbohydrates-0.9no signal · 15%
- Insoluble fibre-0.9no signal · 15%
- Histamine load+0.8no signal · 15%
- Alcohol-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓40
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.8 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 3.3 · butyrate capacity 70/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 63 ms
- Sleep
- 5.9 h
- Steps
- 5,821
- Resting HR
- 71 bpm
Daily log: GI score 36, nutritional resilience 56, adherence 90.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02031 | 30% | S12 | AD-05 | improved | 47 |
| P-02483 | 44% | S06 | BR-03 | no change | 64 |
| P-02280 | 35% | S07 | BR-03 | no change | 50 |
| P-02087 | 31% | S01 | BR-03 | no change | 40 |
| P-02354 | 33% | S01 | CR-01 | improved | 78 |
| P-02491 | 46% | S09 | DT-01 | no change | 65 |
| P-02462 | 43% | S12 | DT-01 | improved | 65 |
| P-02685 | 37% | S16 | DT-01 | improved | 47 |
| P-02218 | 36% | S01 | DT-01 | improved | 61 |
| P-02235 | 36% | S14 | DT-01 | improved | 50 |
| P-02274 | 35% | S15 | DT-01 | improved | 50 |
| P-02339 | 34% | S03 | DT-01 | improved | 50 |